Canada Pension Plan Investment Board Makes New Investment in GRAIL, Inc. $GRAL

Canada Pension Plan Investment Board purchased a new position in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,800 shares of the company's stock, valued at approximately $1,761,000. Canada Pension Plan Investment Board owned approximately 0.06% of GRAIL as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of GRAL. Farallon Capital Management LLC boosted its holdings in shares of GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company's stock valued at $200,510,000 after acquiring an additional 993,684 shares in the last quarter. BlackRock Inc. increased its holdings in GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company's stock worth $244,207,000 after purchasing an additional 608,539 shares in the last quarter. Morgan Stanley raised its position in GRAIL by 63.8% in the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company's stock valued at $129,385,000 after purchasing an additional 588,647 shares during the last quarter. State Street Corp boosted its stake in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company's stock valued at $156,418,000 after purchasing an additional 510,546 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its stake in shares of GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company's stock valued at $178,484,000 after purchasing an additional 455,208 shares in the last quarter.

Insider Transactions at GRAIL

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.83% of the company's stock.

GRAIL Stock Performance

Shares of GRAL stock opened at $80.00 on Monday. GRAIL, Inc. has a 1-year low of $30.82 and a 1-year high of $118.84. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -8.21 and a beta of 3.24. The stock has a 50-day moving average of $70.93 and a 200-day moving average of $63.39.

GRAIL (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts' consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. Sell-side analysts forecast that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on GRAL. The Goldman Sachs Group began coverage on GRAIL in a research note on Friday, June 5th. They issued a "neutral" rating and a $60.00 price objective for the company. Mizuho boosted their target price on shares of GRAIL from $58.00 to $65.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. TD Cowen restated a "buy" rating on shares of GRAIL in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of GRAIL from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Wolfe Research started coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They set a "peer perform" rating for the company. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $67.78.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRAIL, Inc. (NASDAQ:GRAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source